Pelvic local recurrence as first relapse predicts prognosis for clinical stage II/III lower rectal cancer: A clinicopathological investigation

Uda,Shuji; Mukai,Masaya; Kishima,Kyoko; Yokoyama,Daiki; Hasegawa,Sayuri; Koike,Takuya; Tajima,Takayuki; Nomura,Eiji; Tomita,Kousuke; Matsumoto,Tomohiro; Hasebe,Terumitsu; Makuuchi,Hiroyasu

doi:10.3892/mco.2020.2195

Pelvic local recurrence as first relapse predicts prognosis for clinical stage II/III lower rectal cancer: A clinicopathological investigation

Authors:
- Shuji Uda
- Masaya Mukai
- Kyoko Kishima
- Daiki Yokoyama
- Sayuri Hasegawa
- Takuya Koike
- Takayuki Tajima
- Eiji Nomura
- Kousuke Tomita
- Tomohiro Matsumoto
- Terumitsu Hasebe
- Hiroyasu Makuuchi
View Affiliations

Affiliations: Department of Digestive Surgery, Tokai University Hachioji Hospital, Hachioji, Tokyo 192‑0032, Japan, Department of Surgery, Tokai University Tokyo Hospital, Shibuya, Tokyo 151‑0053, Japan, Department of Radiology, Tokai University Hachioji Hospital, Hachioji, Tokyo 192‑0032, Japan
Published online on: December 18, 2020 https://doi.org/10.3892/mco.2020.2195
Article Number: 33
Copyright: © Uda et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the association between the mode of tumor recurrence and prognosis in 123 patients with clinical stage II/III rectal cancer. In the past 10 years, patients received systemic chemotherapy following radical (R0, with no macroscopic residual tumor lesions) resection using total or tumor‑specific mesorectal excision. Patients with rectosigmoid cancer and T4 + chemoradiation therapy were excluded from the present study. The 5‑year relapse‑free survival rate (5Y‑RFS), 5‑year overall survival rate (5Y‑OS), and associations between early post‑operative complications, recurrence mode and prognosis, as well as the 5Y‑OS of patients with relapsed cancer, were calculated. The overall 5Y‑RFS and 5Y‑OS were 71.4 and 83.5%, respectively, and the overall recurrence rate was 22.8% (28/123 patients). Among relapses, remote metastases were observed in 17/123 patients (13.8%): The lung in 8 patients (6.5%), the liver in 5 patients (4.1%) and elsewhere in 4 patients (3.3%). A total of 11 patients (8.9%) had pelvic local recurrence as the first relapse, which was located anterior to the sacrum in 7 patients (5.7%), at the anastomosis site in 2 patients (1.6%), and in the inner pelvis in 2 patients (1.6%). Among relapsed patients, the 5Y‑OS was 69.3% in those with distant metastases and 27.3% in those with local relapse (P=0.02; no significant differences in patient demographics). The results indicated that advanced rectal cancer and control of pelvic local recurrence are manageable by R0 resection and postoperative chemotherapy. However, for patients whose initial relapse was pelvic local recurrence, the relapsed tumor initiated a new metastatic cascade to organs, such as the lung and liver, and affected prognosis.

View Figures

View References

1	Mukai M, Kishima K, Yamazaki M, Aoki H, Izumi H, Yamamoto S, Tajima T, Tobita K, Sadahiro S, Yasuda S and Ogoshi K: Stage II/III cancer of the rectosigmoid junction: An independent tumor type? Oncol Rep. 26:737–741. 2011.PubMed/NCBI View Article : Google Scholar
2	Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, et al: Japanese Society for Cancer of the Colon and Rectum(JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 25:1–42. 2019.PubMed/NCBI View Article : Google Scholar
3	Mukai M, Nakamura M, Kishima K, Ninomiya H, Nomura N, Sato H, Kato N, Machida T, Nakasaki H and Makuuchi H: Local recurrence and occult neoplastic cells in the extranodal fat of dissected lymph nodes in patients with curatively resected primary colorectal cancer. Oncol Rep. 17:1365–1369. 2007.PubMed/NCBI
4	Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A and Cottone M: Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. JAMA. 284:1008–1015. 2000.PubMed/NCBI View Article : Google Scholar
5	Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: A systematic overview of 8,507 patients from 22 randomised trials. Lancet. 358:1291–1304. 2001.PubMed/NCBI View Article : Google Scholar
6	Bosset JF, Collete L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier JC: EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 355:1114–1123. 2006.PubMed/NCBI View Article : Google Scholar
7	Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al: Preoperative radiotherapy with or without concurrent fluorouraciland leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006.PubMed/NCBI View Article : Google Scholar
8	Ozawa H, Kotake K, Hosaka M, Hirata A and Sugihara K: Impact of lateral pelvic lymph node dissection on the survival of patients with T3 and T4 low rectal cancer. World J Surg. 40:1492–1499. 2016.PubMed/NCBI View Article : Google Scholar
9	Kinugasa T, Akagi Y and Shirouzu K: Benefit of lateral lymph node dissection for rectal cancer: Long-term analysis of 944 cases undergoing surgery at a single center (1975-2004). Anticancer Res. 34:4633–4639. 2014.PubMed/NCBI
10	Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, et al: Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): A multicenter, randomized controlled, noninferiority trial. Ann Surg. 266:201–207. 2017.PubMed/NCBI View Article : Google Scholar
11	Tsukamoto S, Fujita S, Ota M, Mizusawa J, Shida D, Kanemitsu Y, Ito M, Shiomi A, Komori K, Ohue M, et al: Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212). Br J Surg. 107:586–594. 2020.PubMed/NCBI View Article : Google Scholar
12	Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B and Gunnarsson U: Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 23:5644–5650. 2005.PubMed/NCBI View Article : Google Scholar
13	Mukai M, Tajima T, Nakasaki H, Sato S, Ogoshi K and Makuuchi H: Efficacy of postoperative adjuvant oral immunochemotherapy in patients with Dukes' B colorectal cancer. Ann Cancer Res Ther. 11:201–214. 2003.
14	Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, et al: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 24:2059–2064. 2006.PubMed/NCBI View Article : Google Scholar
15	Ito I, Mukai M, Ninomiya H, Kishima K, Tsuchiya K, Tajima T, Oida Y, Nakamura M and Makuuchi H: Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncol Rep. 20:1189–1194. 2008.PubMed/NCBI
16	Mukai M, Okada K, Fukumitsu H, Yazawa N, Hoshikawa T, Tajima T, Hirakawa H, Ogoshi K and Makuuchi H: Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer. Oncol Rep. 22:621–629. 2009.PubMed/NCBI View Article : Google Scholar
17	Japanese Society for Cancer of the Colon and Rectum. Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma. 9th edition. Kanehara Shuppan Co. Ltd., Tokyo, pp21-27, 2018.
18	Tajima T, Mukai M, Koike T, Yokoyama D, Uda S, Yoshii H, Higami S, Izumi H, Hasegawa S, Nomura E and Makuuchi H: Better survival after hand-assisted laparoscopic surgery than conventional laparotomy for rectal cancer: Five year results from a single center in Japan. Clin Surg. 2(1368)2017.PubMed/NCBI View Article : Google Scholar
19	Mukai M, Tajima T, Hasegawa S, Yokoyama D, Koike T, Hiraiwa S, Sugiyama T and Tajiri T: Recent molecular immunological chemotherapy for gastrointestinal malignancies. Clin Oncol. 2(1233)2017.
20	Dukes CE: The classification of cancer of the rectum. J Pathol (Bacteriol). 35:323–332. 1932.
21	Furuhata T, Hata F, Tsuruma T, Nshimori H, Yamaguchi K, Mizuguchi T, Kimura Y, Katsuramaki T, Mukaiya M, Sasaki K and Hirata K: Endo-Bowel clamp (PL540S) for safe rectal irrigation in laparoscopy-assisted rectal resection. Surg Today. 34:882–884. 2004.PubMed/NCBI View Article : Google Scholar
22	Cerny M, Dunet V, Prior JO, Hahnloser D, Wagner AD, Meuli RA and Schmidt S: Initial staging of locally advanced rectal cancer and regional lymph nodes comparison of diffusion-weighted MRI with 18F-FDG-PET/CT. Clin Nucl Med. 41:289–295. 2016.PubMed/NCBI View Article : Google Scholar
23	Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, et al: Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: The ACOSOG Z6051 randomized clinical trial. JAMA. 314:1346–1355. 2015.PubMed/NCBI View Article : Google Scholar
24	Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Davies L, Wilson K, Hague W and Simes J: ALaCaRT Investigators. Effect of laparoscopic-assisted resection vs. open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial. JAMA. 314:1356–1363. 2015.PubMed/NCBI View Article : Google Scholar
25	Mukai M, Kishima K, Tajima T, Hoshikawa T, Yazawa N, Fukumitsu H, Okada K, Ogoshi K and Makuuchi H: Efficacy of hybrid 2-port hand-assisted laparoscopic surgery (Mukai's operation) in patients with colorectal cancer. Oncol Rep. 22:893–899. 2009.PubMed/NCBI View Article : Google Scholar
26	Tajima T, Mukai M, Yokoyama D, Higami S, Uda S, Hasegawa S, Nomura E, Sadahiro S, Yasuda S and Makuuchi H: Comparison of hand-assisted laparoscopic surgery (HALS) and conventional laparotomy in patients with colorectal cancer: Final results from a single center. Oncol Lett. 13:4953–4958. 2017.PubMed/NCBI View Article : Google Scholar
27	Kitano S, Inomata M, Mizusawa J, Katayama H, Watanabe M, Yamamoto S, Ito M, Saito S, Fujii S, Konishi F, et al: Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): A phase 3, randomized controlled trial. Lancet Gastroenterol Hepatol. 2:261–268. 2017.PubMed/NCBI View Article : Google Scholar